News & Events – Page 7 – www.brainwork.md

13th July 2018

‘Big Bang’ of Alzheimer’s points to the origin of the disease

https://www.brainwork.md/content/uploads/2018/07/Brainwork-BigBangAlzheimers.jpg 1600 1067 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 13th July 2018 13th July 2018

New research has discovered the precise point at which a healthy protein becomes toxic, offering a window into the very beginnings of Alzheimer’s disease (AD).…

Peter Stevenson, PhD
1
0

5th July 2018

Deep brain stimulation effective in early Parkinson’s tremors

https://www.brainwork.md/content/uploads/2018/07/Brainwork-Parkinsons.jpg 1600 1067 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 5th July 2018 13th July 2018

Deep brain stimulation (DBS) could slow the progression of tremors in Parkinson’s disease (PD), according to new data from a pilot trial.1 Researchers at the…

Peter Stevenson, PhD
0
0

2nd July 2018

The EAN President’s take on medical education

https://www.brainwork.md/content/uploads/2018/07/Brainwork-EANPresident-FranzF.jpg 1024 625 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 2nd July 2018 23rd August 2018

At the recent EAN 2018 congress, we met with Professor Franz Fazekas to discuss important advances and ongoing initiatives in medical education and continuous learning…

Mea Holm, PhD
0
0

22nd June 2018

Headaches and new ways to crush them

https://www.brainwork.md/content/uploads/2018/06/Brainwork-Headachesandnewways.jpg 1800 1195 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 22nd June 2018 13th July 2018

At the ‘conference highlights’ session of the 2018 EAN meeting, Professor Isabel Pavão Martins presented a summary of the most groundbreaking research in the field…

Mea Holm, PhD
1
0

20th June 2018

Rasagiline add-on treatment may offer hope to fast-progressing ALS patients

https://www.brainwork.md/content/uploads/2018/06/MPR425-Brainwork-illustration-brainlines-V00-01-20180619_3_light.gif 8001 4501 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 20th June 2018 13th July 2018

At the ‘late breaking’ session of the EAN 2018 congress, Professor Albert Ludolph from Ulm University (Germany) unveiled the results of a recent double-blind, randomised…

Mea Holm, PhD
0
0

20th June 2018

Revolutionary therapies could make spinal muscular atrophy a distant memory

https://www.brainwork.md/content/uploads/2018/06/MPR425-Brainwork-illustration-DNA-collage-V00-00-20180619.jpg 1200 675 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 20th June 2018 13th July 2018

Cutting-edge molecular and genetic therapies for neurogenic disorders took centre stage at the EAN congress, with novel therapies showcased for the treatment of spinal muscular…

Peter Stevenson, PhD
0
0

19th June 2018

From prognosis to prevention: Alzheimer’s biomarkers hold significant promise for the future

https://www.brainwork.md/content/uploads/2018/06/MPR425-Brainwork-illustration-brainmaze-V00-02-20180619-02.png 1200 675 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 19th June 2018 13th July 2018

Biomarkers could change the landscape of Alzheimer’s disease (AD) forever, but we are only just scratching the surface of their potential, the audience heard during…

Peter Stevenson, PhD
1
0

19th June 2018

The many faces of progressive supranuclear palsy

https://www.brainwork.md/content/uploads/2018/06/Brainwork-TheManyFacesofPSP.jpg 1200 800 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 19th June 2018 13th July 2018

Progressive supranuclear palsy (PSP)—a neurodegenerative disease characterized by tau pathology—can have a variety of clinical presentations, delegates heard at an EAN 2018 forum talk delivered…

Mea Holm, PhD
1
0

7th June 2018

PML risks linked to MS drug duration

https://www.brainwork.md/content/uploads/2018/06/Brainwork-PMLRisks.jpg 1200 797 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 7th June 2018 13th July 2018

Development of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients is linked to treatment medications, not the MS itself, delegates heard at the recent…

Peter Stevenson, PhD
1
0

4th June 2018

New app aims to facilitate cognitive screening of MS patients

https://www.brainwork.md/content/uploads/2018/06/marjan-grabowski-279470-unsplash.jpg 3008 2008 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 4th June 2018 13th July 2018

Dr. Stephen Rao from the Cleveland Clinic (Ohio, USA) presented a new tablet-based screening method for cognitive dysfunction at the Consortium of Multiple Sclerosis Centers…

Mea Holm, PhD
1
0

30th May 2018

Preclinical Alzheimer’s unlikely to lead to dementia, new study reports

https://www.brainwork.md/content/uploads/2018/05/Brainwork-Alzheimers.jpg 1200 829 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 30th May 2018 13th July 2018

New data from a multi-study analysis has unveiled that preclinical Alzheimer’s disease (AD) will not lead to severe dementia in the majority of cases. The…

Peter Stevenson, PhD
0
0

27th May 2018

FDA approves blockbuster migraine treatment

https://www.brainwork.md/content/uploads/2018/05/Brainwork-FDAApproves.jpg 1200 800 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 27th May 2018 13th July 2018

On May 17th, 2018, the US FDA approved Aimovig™ (erenumab) following successful phase III trials. Aimovig™, co-developed by Amgen and Novartis, is the first approved migraine…

Mea Holm, PhD
1
0